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Lung cancer is the most common cause of cancer deaths all over the world, in which
non-small cell lung cancer (NSCLC) accounts for ∼85% of cases. It is well known
that microRNAs (miRNAs) play a critical role in various cellular processes, mediating
post-transcriptional silencing either by mRNA degradation through binding the 3′ UTR
of target mRNA or by translational inhibition of the protein. In the past decade, miRNAs
have also been increasingly identified in biological fluids such as human serum or plasma
known as circulating or cell-free miRNAs, and may function as non-invasive diagnostic
markers for various cancer types including NSCLC. Circulating tumor cells (CTCs) are
those cells that are shed from solid tumors and thenmigrate into the circulation. However,
reports concerning the roles of CTCs are quite rare, which may be attributed to the
difficulties in the enrichment and detection of CTCs in the circulation. Although, there have
been reassuring advances in identifying circulating miRNA-panels, which are assumed
to be of diagnostic value in NSCLC early stage, some issues remain concerning the
reliability of using miRNA panels as a diagnostic tool for NSCLC. In the current review,
we are aiming at providing insights into the miRNAs biology, the mechanisms of miRNAs
release into the bloodstream, cell-free miRNAs as the diagnostic markers for NSCLC and
the current limitations of CTCs as diagnostic markers in NSCLC.
Keywords: NSCLC, circulating miRNAs, miRNA panel, diagnostic value, CTCs detection
INTRODUCTION
Lung cancer is the most common cause of cancer deaths in men and the second leading cause of
cancer deaths in women (Jemal et al., 2010; Ozretic´ et al., 2012). WHO has shown that lung cancer
strikes over 1,605,000 people each year and explains 18.2% of all cancer-related deaths (http://
globocan.iarc.fr). There are two types of lung cancer: small cell lung cancer (SCLC) that is a more
aggressive type and accounts for 15% of cases, and non-small cell lung cancer (NSCLC), which
comprises small squamous cell carcinoma (SCC), adenocarcinoma (AD) and large cell carcinoma
(LCC). Remarkably, NSCLC alone accounts for 85% of cases (Travis et al., 2011; Wood et al., 2012).
With respect to NSCLC, the main reason for the current high mortality is its late diagnosis and
poor prognosis. According to the data from National Cancer Institute, 55% of cases are diagnosed
at an advanced stage and over half of the lung cancer patients die within one year of diagnosis
(SEER Cancer Statistics Review). In addition, the 5-year survival rates vary from 67% in Stage IA
to 39% in Stage IIB, and for patients who were at inoperable advanced stage, the 5-year survival
rates even hardly reach 3.3% (Scagliotti et al., 2003; Jemal et al., 2004). Traditional diagnosis of
NSCLC tends to be based on either computed tomography (CT) scans or chest X-ray following
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histological examination of the tissue. Unfortunately, it has been
estimated that less than 30% of cases can be detected at an early
stage when the curative surgery is possible. The possible reason
may be a lack of reliable biological markers indicative of lung
cancer at earlier stage when tumors are surgically resectable. Thus
far more cases diagnosed are already at an advanced stage when
conventional surgical resection of tumor is impractical due to
the emergence of tumor metastasis. Furthermore, for various
reasons, the tumor tissues tend to be less attainable in clinical
practice. Consequently, it is imperative to find a minimally
invasive marker for NSCLC early diagnosis, thus improving the
prognosis of this disease.
MiRNAs are endogenous small non-coding RNA molecules,
19–22 nucleotides in length, and function as regulatorymolecules
mediating post-transcriptional silencing either by the promotion
of mRNA degradation or by the inhibition of protein translation.
The first miRNA was identified in C. elegans (Lee et al., 1993).
It is well known that miRNAs play a critical role in virtually
all signal pathways in various tumor types. With respect to
NSCLC, a vast number of reports have shown that the difference
betweenmiRNA expression profiles in NSCLC tissues or cell lines
and those in healthy controls might be of diagnostic value for
NSCLC. For instance, Raponi and colleagues have identified 15
differentially expressed miRNAs between SCCs and healthy lung
tissues, among which let-7e and miR-125a were downregulated
while the remaining 13 miRNAs were upregulated (Raponi et al.,
2009). Similarly, another study by Petriella and coworkers have
examined the diagnostic power of miRNAs measurements in
fine-needle aspiration NSCLC biopsies and revealed that three
miRNAs (miR-7, miR-21, miR-155) exhibited a higher level in
tumoral FNA when compared with normal FNA specimens,
while let-7a exhibited a lower level (Petriella et al., 2013). Overall,
one ambitious aim of these researchers is to develop a reliable
miRNA-basedmethod as a convenient tool for the early diagnosis
of lung cancer. However, the inevitable invasiveness of using
resected tumor samples and the unavailability of tumor tissues
limit its routine clinical application. Indeed, not all lung cancer
patients have operable diseases and many of them do not have
available tumor tissues for genetic analysis (Gao et al., 2011). By
contrast, circulating miRNAs in biological fluids such as plasma
are emerging as a non-invasive biomarker for NSCLC diagnosis.
Most importantly, these non-invasive biomarkers are valuable for
predicting drug response by monitoring genetic profiles during
treatment, which holds great potential for personalized therapy.
In 2008, 2 research groups reported that human plasma or
serum contain a huge amount of miRNAs existing in fairly stable
forms, and that these miRNAs profiles hold great promise as
novel non-invasive markers for the early diagnosis of cancers
(Chen et al., 2008; Mitchell et al., 2008). Since then, reports
focusing on the roles of circulating miRNAs in NSCLC have
gradually increased, of which the vast majority are involved in
determining the cell-free miRNAs panels that can discriminate
Abbreviations: MVB, Microvesicular bodies; AGO, Argonaute proteins; MiRISC,
miRNA-induced silencing complex; 3′ UTR, 3′untranslated region; Ldbr, lariat
debranching enzyme; KSRP, KH-type splicing regulatory protein; hnRNP A1,
heterogeneous nuclear ribonucleoprotein A1.
NSCLCs from healthy controls. Apparently, the analysis of
circulating miRNA expression profiles has obvious advantages
over that of tissue or cell line-derived miRNAs.
Circulating tumor cells (CTCs), are a group of cells that are
shed from solid tumors and then migrate into the circulation.
They are widely assumed to be responsible for tumor metastasis
(O’Flaherty et al., 2012; Parkinson et al., 2012). Although, CTCs
are rare in peripheral circulation, it seems to be attractive to
use CTCs as a diagnostic marker of NSCLC, especially when
obtaining adequate tissue from patients for diagnosis is difficult.
The rarity of CTCs necessitates amore sensitive andmore specific
detection technique. However, only a few studies reported thus
far focus on CTC detection and enumeration, most of which
just confirmed the intimate relation between high CTCs numbers
and poor prognosis (Hou et al., 2009; Jorge et al., 2012). With
regard to CTC-associated miRNAs, only a few studies have
been conducted currently to define the subpopulation of CTCs
associating it with the prognosis of NSCLC. In the current review,
we reviewed miRNAs biology, the mechanisms of miRNAs
release into the bloodstream, cell-free miRNAs as diagnostic
markers for NSCLC, and the current limitations of CTCs as
diagnostic markers in NSCLC.
MIRNA BIOSYNTHESIS AND MODE OF
ACTION
There are mainly two different pathways involved in miRNA
biosynthesis: canonical pathway and non-canonical pathway.
The canonical pathway involves a step-wise process starting
from the nucleus and finishing in the cytoplasm, in which
various enzymes and accessory proteins participate. Firstly, long
primary miRNA (pri-miRNA) transcript is transcribed by RNA
polymerase II (Bartel and Chen, 2004). Then, the resulting pri-
miRNA are processed by nuclear RNase III enzyme Drosha and
a cofactor Digeorge syndrome critical region 8 (DGCR8), thus
producing pre-miRNA of ∼70 nt in length (Lund et al., 2004).
Subsequently, the nuclear export of pre-miRNA by Exportin-
5 into the cytoplasm allows nuclease Dicer cleavage, yielding a
paired∼22 nt miRNA/miRNA∗ duplex. Finally, one strand of the
duplex, namely mature miRNA, is loaded into a protein complex
containing Argonaute (AGO) to assemble the RNA-induced
silencing complex (RISC) responsible for gene silencing, with the
remaining strand known as miRNA∗ undergoing degradation.
Afterwards, RISC guided by the mature miRNA binds to the
3′-UTR of target mRNAs resulting in mRNAs degradation or
protein synthesis inhibition (Krol et al., 2010). RISC recognizes
its targetmRNAs byWatson-Crick base pairing betweenmiRNAs
and the “seed sequences” of target mRNA sites.
However, some miRNAs are derived from short hairpin
introns called “mirtrons,” the biosynthesis of which involves
in a non-canonical pathway. This is a splicing-dependent and
Drosha-independent mechanism of miRNA biosynthesis as the
primary transcript is spliced and then debranched by lariat
debranching enzyme (Ldbr) to form pre-miRNA as a Dicer
substrate, which bypasses Drosha/DGCR8 processing (Westholm
and Lai, 2011). It is notable that recent studies also have
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found 5′ and 3′ tailed mirtrons that are very similar to
conventional mirtrons. The difference between them is that
following debranching, tailed mirtrons contain a single-stranded
tail on either 5′ or 3′ of the pre-miRNA-like hairpins, which
needs to be trimmed by an exonuclease known as RNA exosome
to produce pre-miRNAs for Dicer cleavage (Okamura et al.,
2008; Westholm and Lai, 2011). In effect, pre-miRNAs derived
from both conventional miRNAs and mirtrons or tailed mirtrons
are further exported by Exportin-5 into the cytoplasm, where
they are subject to Dicer cleavage to generate miRNA duplex
(Figure 1).
Several RNA-binding proteins are involved in a select
group of miRNA biosynthesis, acting either as “co-activators”
or “co-repressors” for the processing of miRNA precursors.
Among them are the three most important proteins: Cell
lineage abnormal 28 (Lin-28), KH-type splicing regulatory
protein (KSRP) and heterogeneous nuclear ribonucleoprotein A1
(hnRNP A1). Numerous studies have demonstrated that human
paralogs Lin-28a and Lin-28b can prevent the maturation of
let-7 by interacting with pri- or pre-let-7 via the terminal loop
(TL) elements to inhibit their processing by Drosha and Dicer
(Choudhury and Michlewski, 2012; Huang, 2012; Mayr and
Heinemann, 2013). Intriguingly, Lin-28 protein levels are found
to be much higher in undifferentiated cells and the early stages of
embryonic development, while mature let-7 miRNAs are absent
despite the existence of pre-let-7 (Choudhury and Michlewski,
2012). By contrast, KSRP, also known as FBP2, are shown to act as
an auxiliary protein to promote the maturation of select miRNAs
including let-7 by binding to TL elements and interacting with
Drosha and Dicer, which is similar to the way Lin-28 bind to
miRNA precursors (Gherzi et al., 2010). In addition, hnRNP
A1 is one of the most abundant members in the protein family
of hnRNPs. Unlike lin-28 or KSRP, hnRNP A1 either promotes
or inhibits the maturation of miRNAs via different mechanisms
according to the miRNA precursor it interacts with. For example,
Michlewski G and co-workers showed that hnRNPA1 is required
for the processing of pri-miR-18a by binding to its TL element to
induce stem-loop structure rearrangement, thus facilitating more
effective Drosha cleavage (Michlewski et al., 2008; Choudhury
andMichlewski, 2012). However, these authors also have revealed
that hnRNP A1 binds to the TL element of pri-let-7a to inhibit
Drosha cleavage, thus preventing the processing of pri-let-7a.
Most interestingly, they also confirmed the same sequence in the
TL element of pri-let-7a is the target of KSRP and proposed that
hnRNP A1 and KSRP play antagonistic roles in the maturation of
let-7a (Michlewski and Cáceres, 2010). The roles of these protein
factors in the processing of miRNA precursors are shown in
Figure 1.
POSSIBLE MECHANISMS OF MIRNA
ENTERING INTO THE CIRCULATION
As non-invasive serological markers of tumors, circulating
miRNAs are first identified concurrently by two groups in 2008.
Mitchell et al. have demonstrated that circulating miRNAs levels
in human plasma remain stable even when plasma is subjected
to prolonged incubation at room temperature. In addition, they
showed that circulating miRNAs are resistant to multiple freeze-
thaw cycles. Furthermore, they used a mouse model to reveal
that extracellular miRNAs arising from human prostate cancer
xenografts enter the circulatory system (Mitchell et al., 2008).
By Solexa sequencing, Chen et al. (2008) found that compared
to healthy donors, 28 miRNAs species are missing and 63 new
miRNA species are detected in lung cancer patients, suggesting
that human serum might contain miRNA signatures of the
ongoing disease (Chen et al., 2008). These two studies established
the concept that one can diagnose cancers based on specific cell-
free miRNA signatures. In the meantime, a number of intriguing
questions have been posed, among which are the routes of
miRNA release into the circulation.
During the past decade, several research groups have found
that circulating miRNAs can be packaged into some types of
membrane-bound vesicles such as microvesicular bodies (MVB)
or exosomes. Given the remarkable stability of circulating
miRNA, for several years, the predominant view was that the
vast majority of cell-free miRNAs were released from cells in
vesicles (Valadi et al., 2007; Zernecke et al., 2009; Collino et al.,
2010). However, others have revealed that cell-free miRNAs also
exist in vesicle-free forms associating with protein complexes
including high and low density lipoproteins and RNA-binding
proteins (Wang et al., 2010; Arroyo et al., 2011; Vickers et al.,
2011). For instance, Arroyo JD have shown that Argonaute2
(AGO2), the key effector protein of miRNA-mediated silencing,
is present in human plasma and serve as a significant carrier of
circulating miRNAs in plasma as shown in Figure 1. They also
found that potentially 90% of circulating miRNAs are present
in vesicle-free form, which suggest that circulating miRNA
biomarker analysis based only on exosome purification might be
ineffective for miRNA biomarkers that circulate as nonexosomal
AGO2 complexes (Arroyo et al., 2011). Additionally, Vicker KC
et al. have demonstrated that high-density lipoprotein particles
(HDL) transport endogenous miRNAs and deliver them to
recipient cells, the process of which is regulated by neutral
sphingomyelinase and dependent on scavenger receptor class B
type I (Vickers et al., 2011). Moreover, vesicle-associatedmiRNAs
versus vesicle-free miRNAs may originate from different cell
types and indicate cell-type specific miRNA release mechanisms.
For example, miR-122, a liver-specific miRNA, circulates only in
protein-associated form, suggesting that hepatocytes releasemiR-
122 via protein carrier pathway (Chang et al., 2004). By contrast,
miRNAs primarily present in membrane-bound vesicles, such
as let-7a, may originate from cell types that generate vesicles
(Arroyo et al., 2011). However, the relative abundance of vesicle-
derived miRNAs versus vesicle-free miRNAs for any given
miRNA species remains to be explored.
CIRCULATING MIRNAS AS DIAGNOSTIC
BIOMARKERS OF NSCLC
The non-invasiveness, stability and reproducibility make
circulating miRNAs an ideal diagnostic marker in oncology and
hold great promise for clinical applications. Since circulating
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FIGURE 1 | MiRNA biosynthesis through canonical and non-canonical pathways and the mechanisms of miRNA release into the bloodstream
(Modified from Zandberga et al., 2013). Mirtrons are spliced, and then debranched by lariat debranching enzyme (Ldbr) to generate pre-miRNAs, the product of
Drosha/DGCR 8 cleavage of pri-miRNAs in canonical pathways. Pre-miRNAs from both pathways are exported into the cytoplasm by Exportin 5 for further processing
by Dicer, thus producing double-stranded miRNA/miRNA* duplexes. Subsequently, one strand of this duplex is loaded into miRNA induced silencing complex
(miRISC) containing one of four AGOs (such as AGO2 as shown), GW182 and various unknown GW182-interacting silencing effectors, leaving the other strand
undergoing degradation. The mature miRNA then guides the miRISC to bind to the 3′ UTR of target mRNAs either to promote mRNA degradation or to inhibit protein
translation. KSRP as a co-activator and Lin-28 as a co-repressor bind to the terminal loop (TL) elements of pri or pre-miRNAs to promote and inhibit the maturation of
a subset of miRNA precursors respectively. HnRNP A1 can both promote (for pri-miR-18a) and inhibit (for pri-let-7a) the processing of miRNAs by binding to the TL
elements of pri-miRNAs as shown in the figure, which is mediated by different mechanisms. Circulating miRNAs exist either as a vesicle-associated form or as a
protein-associated form in the circulation. The former (vesicles) include exosomes and microvesicles. The latter (proteins) include high and low density lipoproteins,
RNA binding proteins such as Argonaute 2.
miRNAs were first identified in human plasma in 2008, a great
many of studies have been aiming at identifying a reliable
diagnostic tool by investigating the differential expression of
circulating miRNAs between NSCLC patients and healthy
controls or patients harboring benign tumors. For instance,
Lihong Fan et al. have demonstrated that a predictive model
combining serum miR-15b-5p, miR-16-5p, miR-20a-5p can
be used to discriminate the early stage of NSCLC cases from
healthy subjects (Fan et al., 2015). Reassuringly, the fact that
this study applied two different methods (RT-qPCR and Nano-
quantum dots microarray) to identify the same differential
expression of serum miRNAs, which may have improved the
sensitivity and reproducibility of the results. Additionally, Li
Y et al. have isothermally sensitively detected lung cancer-
associated serum miR-486-5p through hairpin probe-based
rolling circle amplification (HP-RCA) with superhigh sensitivity
(Li et al., 2013). In practice, miR-486-5p has been shown to be
downregulated in both the primary cancer and the serum of
NSCLC patients in several independent research groups (Volinia
et al., 2006; Boeri et al., 2011; Shen et al., 2011), which suggests
this miRNA might serve as a tumor suppressor involved in
multiple signaling circuits in NSCLC and thus deserves highly
attention in future study. Furthermore, a 34-miRNA panel in
serum has been identified in patients at the early stage of NSCLC
in a group of asymptomatic high-risk subjects with up to 80%
accuracy (Bianchi et al., 2011). The signature obtained in this
study allows the diagnosis of asymptomatic patients instead
of symptomatic ones diagnosed by other signatures in many
previous studies. Most importantly, it is specific for lung cancer
compared with breast cancer. However, the researchers of this
study may well test for the specificity of this signature in other
more cancer types other than breast cancer before its clinical
application. Moreover, using three different analytical methods,
A. Markou and colleagues identified an eight miRNA-panel
which can be used for discriminating cancerous tissues from
non-cancerous ones in NSCLC patients. By contrast, only
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three of these miRNAs (miR-30e-5p, miR-21 and miR-10a) are
differentially expressed in NSCLC plasma specimens compared
to that from healthy plasma, suggesting miRNA profiles in
the circulation may not necessarily reflect exactly those in
tumor tissues (Markou et al., 2013). However, an earlier report
have showed that miRNA footprints did not show significant
difference between circulating exosome-derived miRNAs and
the tumoral miRNAs profiles using 4 lung cancer tissues and
their corresponding plasma samples (Rabinowits et al., 2009).
This contradiction between these two studies may be attributed
to two factors: one is that the internal control gene used for the
normalization of miRNA expression may vary between different
research groups; the other is that circulating miRNAs do not exist
only in exosomes as mentioned earlier, most of them are shown
to be associated with protein complexes. Most importantly,
only 4 lung cancer tissues used for the study are not enough to
represent a reliable result.
In the past two years, a vast number of efforts have been made
to identify circulating miRNA panels for NSCLC early diagnosis.
However, many of these studies remain to be validated given the
inconsistency of reference controls used for the normalization
and of the materials such as exosomes, serum and whole blood
used for RNA isolation. For instance, Magdalena B. Wozniak
and colleagues showed that a 24-miRNA panel alone could
distinguish lung cancer patients from healthy controls with an
AUC of 0.92, and they also revealed that this diagnostic power
can be further enhanced by adding factors such as age, sex and
smoking status into this model (Wozniak et al., 2015). Similarly,
6 cell-free miRNAs (200b, 429, 205, 125b, 34b, 203) have also
been validated with an even higher abundance in the serum
of NSCLC patients compared to healthy subjects (Halvorsen
et al., 2016). However, a common problem in these two studies
is that the authors have chosen U6 as the internal control for
the normalization when analyzing the miRNAs profiles, which
may be inaccurate as U6 has been reported to be not a suitable
endogenous control for the quantification of cell-free miRNAs
(Benz et al., 2013; Xiang et al., 2014). Therefore, it is conceivable
that the conclusions obtained from those studies should be
interpreted with caution. In addition, Silva et.al reported that
the levels miR-30e-3p, let-7f and miR-20b, were downregulated
in the plasma vesicles of NSCLC cases compared with healthy
controls (Silva et al., 2011). Another similar study showed that
a panel of miRNAs (30b, 30c, 103, 122, 195, 203, 221, 222) in
exosomes from the plasma displayed significantly differential
expression between NSCLC cases and healthy donors, which
might suggest the possibility that miRNAs signatures from
patient exosomes could alone represent the status of ongoing
disease (Giallombardo et al., 2016). However, these studies might
not be complete as researchers focused only on vesicle-associated
miRNAs, such as exosomes, probably missing the differential
expression of vesicle-free miRNAs that may represent a larger
proportion of miRNAs in the circulation and thus producing
an inaccurate result. Most of the reported results identifying
circulating miRNA panels as diagnostic biomarkers in the last
two years are summarized in following Table 1. As shown in the
table, different miRNA-panels have been identified by different
research groups. Actually, some above mentioned factors such as
various biological materials and different internal controls used
may account for this phenomenon.
Although, there do exist some concerns about current
studies of circulating miRNAs, some critical miRNAs as tumor
suppressors or oncogenes are of great value to develop miRNA-
based strategy for lung cancer therapy and therefore should be
prioritized to further studies with respect to their diagnostic
power. Among these critical miRNAs, miR-21 is a known to
be an “oncomir” and is commonly overexpressed in cancers
including lung, breast and colorectal cancer (Ma et al., 2014). For
example, Si ML and colleagues showed that miR-21 inhibition
suppresses tumor growth in xenograft mouse model and
increases cell apoptosis that is associated with downregulation of
bcl-2 expression in breast cancer (Si et al., 2007). Also, higher
expression of miR-21 and miR-155 in both tumor tissues and
serum can predict recurrence and poor survival in NSCLC
(Yang et al., 2013). This may suggest that overexpression of
circulating miR-21 holds great prognostic potential in NSCLC.
Another aspect about miR-21 is that it influences response to
chemotherapy in several tumor types and thus can act as a
therapeutic target for overcoming drug resistance in cancers. For
instance, a recent study has revealed that antisense inhibition
of miR-21 or miR-221 sensitizes the effects of Gemcitabine, a
chemotherapeutic treatment of pancreatic cancer (Park et al.,
2009). By contrast, let-7 family miRNAs are known as tumor
suppressors and down-regulation of let-7 expression has been
demonstrated in breast, prostrate, ovarian and lung cancers
(Boyerinas et al., 2010). Dejuan Kong et al. have provided
evidence that let-7 loss mediates up-regulation of EZH2 and
contributes to PCa aggressiveness, which can be attenuated by B-
DIM, a potent agent in inhibiting the growth of Pca cells (Kong
et al., 2012). In addition, numerous studies have revealed that
let-7 acts as a promising therapeutic target for lung cancer. For
example, Trang.s group have shown that systematical delivery of
synthetic let-7 mimic or miR-34a into lung tumor-bearing mice
results in significant tumor regression compared to the delivery
of a miRNA control (Trang et al., 2011). Overall, since current
studies on the roles of miR-21 and let-7 family in various cancer
types have mainly focused on tumor tissues, circulating miR-21
and let-7 in plasma warrant further validation before applying
them as biomarkers for the early diagnosis of cancers including
NSCLC.
CURRENT LIMITATIONS ON CTCS AS
DIAGNOSTIC MARKERS OF NSCLC
CTCs are tumors cells which are released from solid tumors,
and then migrate into the circulation and play a critical role
in tumor metastasis. However, CTCs are extremely rare, and
they can be detected at a low frequency of 1 CTCs per 106-107
leukocytes (Young et al., 2012). Initially, CTCs were considered
as non-leukocytic cells with epithelial origin since they have
been detected in various epithelial cancers such as breast cancer,
lung cancer and colon cancer (Allard et al., 2004). Consequently,
epithelial marker-based methods for the detection of CTCs have
been widely used (Hardingham et al., 1993; Liljefors et al., 2005).
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TABLE 1 | Circulating miRNAs as diagnostic markers for NSCLC.
Significantly-expressed miNRAs Scope Sample Technique Normalization References
let-7c, miR-152 (down) 120 NSCLCs vs. 360 HCs Plasma qRT-PCR U6 Dou et al., 2015
miR-16-5p, miR-17b-5p, miR-19-3p,
miR-20a-5p, miR-92-3p (down)
miR-15b-5p(up)
Training set: 94 NSCLCs vs. 58HCs,
Validation set: 70 NSCLCs vs. 54 HCs
Serum TaqMan miRNA assays Absolute
quantification
Fan et al., 2015
miR-148/152 family (Down) miR-944,
miR-3662 (up) miR-483-5p, miR-193a-3p,
miR-25, miR-214 miR-7 (up)
20 NSCLCs with BPD VS.10 HCs 90
NSCLCs vs. 85 HCs 221 NSCLCs,
161 HCs, 56 with benign nodules
Serum
Plasma
RT-qPCR RT-qPCR
TaqMan Low Density Array,
RT-qPCR
U6 U6 let-7d/g/i
trio
Chen et al., 2015;
Li et al., 2015;
Powrózek et al.,
2015
miR-125a-5p, miR-145 miR-146a (up) 70 NSCLCs vs. 70 HCs Serum RT-qPCR miR-39 Wang et al., 2015
A panel of 24 miRNAs (Relative
expression)
100 NSCLCs vs. 100 HCs Plasma TaqMan MiRNA Arrays U6snRNA
ath-miR-159a
Wozniak et al.,
2015
A panel of 8 miRNAs (Relative expression) 12 NSCLCs vs. 6 HCs Exosomes RT-PCR mir-1228-3p Giallombardo
et al., 2016
miR-429, miR-205, miR-200b, miR-203,
miR-125b miR-34b (up)
38 NSCLCs, 16 patients with COPD,
16 HCs
Serum TaqMan Low Density
Arrays
U6 Halvorsen et al.,
2016
NSCLCs, NSCLC patients; HCs, healthy controls; RT-PCR, real-time reverse transcription quantitative polymerase chain reaction; COPD, chronic obstructive pulmonary disease; BPD,
benign pulmonary diseases.
Nevertheless, recent studies have shown that the morphological
characteristics of CTCs have yet to be well defined and may
vary according to tumor stages (Parkinson et al., 2012). Overall,
more clear phenotypes of CTCs as a “liquid biopsy” remain to be
explored in future study.
As a “liquid biopsy,” current studies on CTCs as a biomarker
of NSCLC have been limited to its enrichment and detection
as well as its relation to NSCLC prognosis. For instance, Laura
Muinelo-Romay and colleagues found that patients with CTCs
>5 are assumed to correlate with poorer prognosis based
on CTCs counts using CellSearch technology (Muinelo-Romay
et al., 2014). Another group have isolated CTCs by cell size
filtration and shown that CTCs can be identified in two-thirds of
patients at advanced stage of NSCLC at diagnosis, suggesting that
CTCs counts may reflect the ongoing disease status of NSCLC
(Mascalchi et al., 2016).
However, less progress has been made in the field of CTCs
as an ideal biomarker for NSCLC diagnosis, and this may
result from several aspects. For one thing, various techniques
for CTCs enrichment and later detection have been developed
which base either on physical properties such as size, density
and electric charges, or on biological properties such as the
expression of CTCs surface marker (Alix-Panabieres and Pantel,
2013), among which the most widely used method relies on
the epithelial protein, namely, Epithelial cell adhesion molecule
(Ep-CAM) for the CTCs enrichment (Allard et al., 2004; Harb
et al., 2013; Haus et al., 2014). However, Hanssen A et al.
reported that the expression Ep-CAM may be downregulated in
CTCs experiencing epithelial-to-mesenchymal transition (EMT),
which raises the concern that this Ep-CAM based CTCs
enrichment method may lose EMT-associated CTCs (Hanssen
et al., 2016). Additionally, another group, Yingchun Man et.al
have developed four CTCs markers (CK7, CLCA2, HMMR
and hTERT) to detect CTCs, which significantly improves the
specificity and sensitivity of CTC detection (Man et al., 2014).
Intriguingly, by miRNA in situ hybridization, Francisco G.
Ortega et al. have identified miR-21 within CTCs as a marker
used for detecting CTCs displaying an EMT phenotype (Ortega
et al., 2015). We can infer that miR-21 may be function as an
oncomir implicated in tumor metastasis. In a nutshell, whether
epithelial maker-dependent or -independent approach is more
sensitive and specific in CTCs enrichment and detection remains
to be explored. For another thing, CTCs counts alone may not
fully represent the ongoing NSCLC status especially at a very
early stage. This concept is clearly intelligible given that several
results have shown CTCs heterogeneity as a diagnostic marker
by identifying different CTCs subpopulations. In a research
reported by Wu et al. (2015), three CTCs subpopulations,
epithelial CTCs, biophenotypic epithelial/mesenchymal CTCs
and mesenchymal CTCs, were identified using epithelial-to-
mesenchymal transition markers, which is useful to identify
the more aggressive CTC phenotypes and thus facilitates the
determination of clinical practice.
DISCUSSION
NSCLC diagnosis, especially at early stage is in great demand
in clinical practice. Conventional diagnostic applications relying
on tissue biopsy either through computed tomography scans
or chest X-ray have remarkable limitations given their low
sensitivity and invasiveness as well as tissue unavailability.
Consequently, a novel, reliable and reproducible diagnostic
biomarker is badly needed to obtain an earlier and more accurate
diagnosis result.
Circulating miRNAs in biological fluids, especially in human
plasma or serum, have emerged as a non-invasive diagnostic
marker for NSCLC. In the past five years, studies in this
field have identified different miRNA panels in the circulation
with higher sensitivity plus higher specificity in early NSCLC
diagnosis, which might be preferable compared to any single
miRNA used for NSCLC diagnosis. In addition, several factors
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may contribute to the fact that different miRNA panels have
been identified for NSCLC diagnosis. To begin with, different
materials such as plasma/serum, whole blood, or exosomes
used for cell-free miRNAs isolation make it possible that the
quality and quantity of circulating miRNAs isolated by different
researcher vary according to biological material types. Indeed,
whole blood also contains a large amount of peripheral blood
mononuclear cells (PBMCs) compared with serum or plasma.
Intriguingly, a two-miRNA panel (miR-19b-3p and miR-29b-
3p) arising from PBMCs have been developed by Jie Ma et al.
to discriminate NSCLCs from healthy persons with 72.62%
sensitivity and 82.61% specificity. This group also identified
SCC, the major type of NSCLC using this two-miRNA panel,
with 80.00% sensitivity and 89.86% specificity, which may imply
that only focusing on serum-derived circulating miRNAs may
not be enough to reflect a reliable result in terms of NSCLC
diagnosis based on circulating miRNA detection (Ma et al.,
2015). In addition, the inconsistency of the methods used
for data analysis should also be considered to account for
the existence of various miRNA-panels. As shown in Table 1,
internal controls such as U6 and miR-39 have been used
for the normalization of miRNA expression. Unfortunately,
the high variability of non-coding RNAs including rRNAs,
U6 snRNA and snoRNAs in the plasma microvesicles and
their readily degradation in serum have been reported, which
indicates that such non-coding RNAs may be inappropriate
as endogenous controls (Chen et al., 2008). On a whole,
more validations on the whole blood are warranted to identify
circulating miRNA biomarkers that are of diagnostic value,
coupled with a uniform and reliable internal control for data
analysis.
CTCs are another type of “liquid biopsy” ideal for the
diagnosis of NSCLC. Several issues remain to be addressed with
respect to CTC enrichment and detection. Firstly, the platform
of CTC detection technology combining marker-dependent (Cell
Search) and marker-independent approaches (Isolation by size
of epithelial tumor cells) has proven to be more sensitive than
either of the two methods alone could be (Krebs et al., 2012).
In addition, CTC-associated miRNAs, such as miR-21, can be
applied to detect CTCs with an EMT phenotype (Ortega et al.,
2015). We may hypothesize here CTC-associated miRNAs are
likely to contain a larger amount of information underlying
NSCLC cases, not merely being used as a marker for detection
of CTCs. On the whole, future validation about such work is
warranted before routine clinical applications are available.
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